NR3C1 and newborn respiratory distress syndrome: Current obstetrical guidelines mandate antenatal glucocorticoid receptor agonists (dexamethasone/betamethasone) as the standard intervention for preterm birth risk mitigation during gestational weeks 23–34, targeting fetal lung tissue maturation to prevent neonatal respiratory distress syndrome [15].